199 related articles for article (PubMed ID: 25241290)
1. Oversulfated heparins with low anticoagulant activity are strong and fast inhibitors of hepcidin expression in vitro and in vivo.
Poli M; Asperti M; Ruzzenenti P; Mandelli L; Campostrini N; Martini G; Di Somma M; Maccarinelli F; Girelli D; Naggi A; Arosio P
Biochem Pharmacol; 2014 Dec; 92(3):467-75. PubMed ID: 25241290
[TBL] [Abstract][Full Text] [Related]
2. Low anticoagulant heparin-iron complex targeting inhibition of hepcidin ameliorates anemia of chronic disease in rodents.
Li L; Wang X; Zhang H; Chen Q; Cui H
Eur J Pharmacol; 2021 Apr; 897():173958. PubMed ID: 33610598
[TBL] [Abstract][Full Text] [Related]
3. Glycol-split nonanticoagulant heparins are inhibitors of hepcidin expression in vitro and in vivo.
Poli M; Asperti M; Naggi A; Campostrini N; Girelli D; Corbella M; Benzi M; Besson-Fournier C; Coppin H; Maccarinelli F; Finazzi D; Arosio P
Blood; 2014 Mar; 123(10):1564-73. PubMed ID: 24398330
[TBL] [Abstract][Full Text] [Related]
4. Non-Anticoagulant Heparins Are Hepcidin Antagonists for the Treatment of Anemia.
Poli M; Asperti M; Ruzzenenti P; Naggi A; Arosio P
Molecules; 2017 Apr; 22(4):. PubMed ID: 28397746
[TBL] [Abstract][Full Text] [Related]
5. Pentosan polysulfate to control hepcidin expression in vitro and in vivo.
Asperti M; Denardo A; Gryzik M; Castagna A; Girelli D; Naggi A; Arosio P; Poli M
Biochem Pharmacol; 2020 May; 175():113867. PubMed ID: 32088260
[TBL] [Abstract][Full Text] [Related]
6. High Sulfation and a High Molecular Weight Are Important for Anti-hepcidin Activity of Heparin.
Asperti M; Naggi A; Esposito E; Ruzzenenti P; Di Somma M; Gryzik M; Arosio P; Poli M
Front Pharmacol; 2015; 6():316. PubMed ID: 26955355
[TBL] [Abstract][Full Text] [Related]
7. Heparin from bovine intestinal mucosa: glycans with multiple sulfation patterns and anticoagulant effects.
Tovar AM; Capillé NV; Santos GR; Vairo BC; Oliveira SN; Fonseca RJ; Mourão PA
Thromb Haemost; 2012 May; 107(5):903-15. PubMed ID: 22437650
[TBL] [Abstract][Full Text] [Related]
8. [Anticoagulant activity of low-molecular-weight heparins obtained using a hydrolase complex].
Drozd NN; Tolstenkov AS; Bannikova GE; Miftakhova NT; Lapikova ES; Makarov VA; Varlamov VP
Eksp Klin Farmakol; 2007; 70(6):19-24. PubMed ID: 18318190
[TBL] [Abstract][Full Text] [Related]
9. Heparin: a potent inhibitor of hepcidin expression in vitro and in vivo.
Poli M; Girelli D; Campostrini N; Maccarinelli F; Finazzi D; Luscieti S; Nai A; Arosio P
Blood; 2011 Jan; 117(3):997-1004. PubMed ID: 21076043
[TBL] [Abstract][Full Text] [Related]
10. [Reversal for heparins and new anticoagulant treatments].
Kortchinsky T; Vigué B; Samama CM
Ann Fr Anesth Reanim; 2013 Jan; 32(1):37-49. PubMed ID: 23273505
[TBL] [Abstract][Full Text] [Related]
11. Heparin and low molecular weight heparin in thrombosis and beyond.
Mousa SA
Curr Opin Investig Drugs; 2002 Aug; 3(8):1181-6. PubMed ID: 12211411
[TBL] [Abstract][Full Text] [Related]
12. Generation of anti-factor Xa active, 3-O-sulfated glucosamine-rich sequences by controlled desulfation of oversulfated heparins.
Naggi A; De Cristofano B; Bisio A; Torri G; Casu B
Carbohydr Res; 2001 Dec; 336(4):283-90. PubMed ID: 11728396
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of rat smooth muscle cell adhesion and proliferation by non-anticoagulant heparins.
Kazi M; Lundmark K; Religa P; Gouda I; Larm O; Ray A; Swedenborg J; Hedin U
J Cell Physiol; 2002 Dec; 193(3):365-72. PubMed ID: 12384988
[TBL] [Abstract][Full Text] [Related]
14. Biochemical studies on sulfated lactobionic acid amides.
Klauser RJ; Meinetsberger E; Raake W
Semin Thromb Hemost; 1991; 17 Suppl 1():118-25. PubMed ID: 1648790
[TBL] [Abstract][Full Text] [Related]
15. The activity of unfractionated heparin and low molecular weight heparins in rabbit plasma--the need for using absolute anti-factor Xa and antithrombin activities.
Peyrou V; Béguin S; Boneu B; Hemker HC
Thromb Haemost; 1997 Feb; 77(2):312-6. PubMed ID: 9157588
[TBL] [Abstract][Full Text] [Related]
16. Comparative human pharmacology of low molecular weight heparins.
Harenberg J; Stehle G; Augustin J; Zimmermann R
Semin Thromb Hemost; 1989 Oct; 15(4):414-23. PubMed ID: 2554502
[TBL] [Abstract][Full Text] [Related]
17. Comparison of low molecular weight heparins and unfractionated heparin after successive subcutaneous administration. A randomized controlled study in healthy volunteers.
Pindur G; Heiden M; Köhler M
Arzneimittelforschung; 1993 May; 43(5):542-7. PubMed ID: 8392345
[TBL] [Abstract][Full Text] [Related]
18. Effects of sulfation on antithrombin-thrombin/factor Xa interactions in semisynthetic low molecular weight heparins.
Sissi C; Naggi A; Torri G; Palumbo M
Semin Thromb Hemost; 2001 Oct; 27(5):483-7. PubMed ID: 11668417
[TBL] [Abstract][Full Text] [Related]
19. Ultrasonic-assisted preparation of a low molecular weight heparin (LMWH) with anticoagulant activity.
Achour O; Bridiau N; Godhbani A; Le Joubioux F; Bordenave Juchereau S; Sannier F; Piot JM; Fruitier Arnaudin I; Maugard T
Carbohydr Polym; 2013 Sep; 97(2):684-9. PubMed ID: 23911501
[TBL] [Abstract][Full Text] [Related]
20. Molecular and pharmacologic profile of tinzaparin and a comparable low-molecular-weight bacterial sulfaminoheparosan.
Maddineni J; Ma Q; Hoppensteadt DA; Demir M; Manoni M; Cornelli U; Fareed J
Clin Appl Thromb Hemost; 2004 Jan; 10(1):27-37. PubMed ID: 14979402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
